Hitachi is a pioneer in developing sophisticated scientific and medical systems and products. Hitachi fulfills the modern healthcare requirements by continually working toward development of new medical diagnostics products and biotechnology equipment. Hitachi also offers a comprehensive line of cutting-edge scientific equipment for a wide range of research applications.
Hitachi High Technologies America offers a wide breadth of product and service offerings which include semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products.
Provides technologically advanced solutions to meet the diverse and complex challenges of materials science, biological research, and industrial manufacturing. Hitachi supports national laboratories, R&D facilities, and academia with a wide range of reliability-proven instrumentation, including scanning electron microscopy (SEM), analytical and biological transmission electron microscopy (TEM), dedicated STEM, focused ion beam (FIB), tabletop microscopes, atomic force microscopy (AFM), and microanalysis sample preparation systems.
Supports government researchers by fulfilling their need for scientific instrumentation via a wide range of reliability-proven offerings, including liquid chromatography, amino acid analyzers, UV-Vis/NIR and fluorescence spectroscopy systems, thermal analyzers, and X-ray fluorescence (XRF) solutions.
Hitachi Medical Systems America (HMSA), a wholly owned subsidiary of Hitachi Healthcare Business Unit offers a broad range of diagnostic imaging equipment including MRI and CT. Our innovations in diagnostic imaging provide technology that drives clinical solutions to deliver diagnostic confidence, improve workflow efficiency and provide a better patient experience. In addition to exceptional equipment, HMSA is known for its comprehensive customer support programs to maximize the lifecycle value of equipment through responsive service maintenance, significant software upgrades and on-going applications support.
Oasis 1.2T MRI system sets a high standard for patient-centric care. A unique achievement in high-performance imaging, the Oasis truly open architecture features advanced magnet design, Zenith RF Technology and robust clinical capabilities to achieve high throughput diagnostic performance.
With an unobstructed viewing angle and the industry’s most accommodating patient table, no other MRI system enables you to capture and retain as broad of a patient demographic as Oasis. Even the most challenging patients can be handled with confidence, without compromising on safety, performance, or efficiency
Oasis 1.2T MRI
Designed around the shape of the body to accommodate the broadest patient spectrum, Echelon Oval embodies our innovative spirit and unwavering commitment to patient comfort without compromising image quality.
Echelon Oval brings together all the key attributes of a leading 1.5T MR system – patient accessibility, workflow, and clinical capabilities all covered by Hitachi’s industry leading customer support.
Echelon Oval 1.5T MRI
Advancing the technology of Computed Tomography for over 30 years, Hitachi is a recognized innovator of lower dose, high diagnostic value CT solutions. The Scenaria scalable CT platform provides superior value with patient-friendly imaging by combining the newest lower-dose features with rapid workflow and the benefits of a standard lateral shift patient table for easier patient positioning and lower dose.
Scenaria SE 64/128 CT
With Supria experience a high level of 16-Slice CT image quality across a wide range of applications. Access the latest dose awareness, reduction and management features. And take advantage of a compact footprint, increased patient access and lower cost of ownership of Supria.
Supria is designed with the patient in mind. It’s large aperture, long table and high weight capacity comfortably accommodates patients of all sizes up to 500lbs.
Supria 16-Slice CT
Hitachi Aloka Medical America, Inc. is committed to delivering advanced diagnostic ultrasound systems to meet the needs of physicians and patients. As the longest operating ultrasound company in the world Hitachi Aloka Medical has led the medical industry by pioneering ultrasound systems that have advanced the standard of real time imaging. We design and develop innovative consoles, transducers, software and related products that are used to help medical professionals deliver proactive solutions to diagnose and treat patients and deliver the best patient care possible.
ARIETTA 70 Ultrasound System
Having made significant and noteworthy contributions in the field of ultrasound technology, including introducing the world’s first commercialized medical ultrasound equipment back in 1960, Hitachi Aloka Medical is poised to continue the advancement of its ultrasound business. In 2011, Hitachi Aloka Medical, Inc. introduced yet another first with the robotically-controlled ultrasound transducer giving surgeons direct control of the real-time imaging during minimally invasive Robotic Partial Nephrectomy (RAPN) procedures.
Robotically-Controlled Ultrasound Transducer
With its international headquarters in Tokyo, Japan, Hitachi Aloka Medical, Ltd. encompasses the ultrasound division of both Hitachi Medical Corporation and Aloka Co., Ltd. The company centralized its U.S. and Canada business operations in Wallingford, CT and Hitachi Aloka Medical America, Inc. employs local sales, service and clinical applications professionals across the U.S. and Canada.
Noblus Ultrasound System
Hitachi has developed a reliable, stable and user-friendly charged particle therapy system (PROBEAT) which meets the growing needs of new and innovative solutions for cancer therapy. Charged particles can be delivered at very high speed, penetrating the body and releasing maximum energy to the targeted tumor. As a result, exposure of normal tissue to radiation is minimized, and higher radiation dose can be administered to the tumor area.
Hitachi has over 20 years of proven particle therapy technology experience and continues to define new technological limits by developing innovative analysis and fabrication techniques. In the future, Hitachi intends to continue to stay at the technology’s cutting edge of charged particle cancer therapy by enhancing the capabilities of the synchrotron accelerator for delivery of increasingly heavier particles such as carbon.